Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum-implications for therapeutic targets to prevent encapsulating peritoneal sclerosis

Peritoneal Dialysis International

Volumn 31, Issue 3, 2011, Pages 291-300

  Braun, Niko ^a   Fritz, Peter ^a   Biegger, Dagmar ^a   Kimmel, Martin ^a   Reimold, Fabian ^a   Ulmer, Christoph ^a   Dominik Alscher, M ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Encapsulating peritoneal sclerosis; Glucocorticoid receptor; Matrix metalloproteinase 9; Tamoxifen; Target; TGF 1; Vitamin D

Indexed keywords

ANDROGEN; CELL NUCLEUS RECEPTOR; ESTROGEN RECEPTOR; GELATINASE B; GLUCOCORTICOID; HORMONE RECEPTOR; PROGESTERONE; RECOMBINANT TRANSFORMING GROWTH FACTOR BETA1; TAMOXIFEN; VITAMIN D;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HERNIOPLASTY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFLAMMATORY CELL; MALE; PERITONEAL DIALYSIS; PERITONEAL FIBROSIS; PERITONITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TREATMENT DURATION; UREMIA;

ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; PERITONEAL FIBROSIS; PERITONEUM; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSFORMING GROWTH FACTOR BETA1;

EID: 83755185391     PISSN: 08968608     EISSN: 17184304     Source Type: Journal    
DOI: 10.3747/pdi.2010.00118     Document Type: Article

References (43)

1. Brown MC, Simpson K, Kerssens JJ, Mactier RA. Encapsulating peritoneal sclerosis in the new millennium: a national cohort study. Clin J Am Soc Nephrol 2009; 4:1222-9.
2. Johnson DW, Cho Y, Livingston BE, Hawley CM, McDonald SP, Brown FG, et al. Encapsulating peritoneal sclerosis: incidence, predictors, and outcomes. Kidney Int 2010; 77:904-12.
3. Kawanishi H, Kawaguchi Y, Fukui H, Hara S, Imada A, Kubo H, et al. Encapsulating peritoneal sclerosis in Japan: a prospective, controlled, multicenter study. Am J Kidney Dis 2004; 44:729-37.
4. Plum J, Hermann S, Fussholler A, Schoenicke G, Donner A, Rohrborn A, et al. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties. Kidney Int Suppl 2001; 78:S42-7.
5. Garosi G, Cappelletti F, Di Paolo N. Fibrosis and sclerosis: different disorders or different stages? Contrib Nephrol 2006; 150:62-9.
6. Alscher DM, Braun N, Biegger D, Fritz P. Peritoneal mast cells in peritoneal dialysis patients, particularly in encapsulating peritoneal sclerosis patients. Am J Kidney Dis 2007; 49:452-61.
7. Braun N, Alscher DM, Fritz P, Edenhofer I, Kimmel M, Gaspert A, et al. Podoplanin-positive cells are a hallmark of encapsulating peritoneal sclerosis. Nephrol Dial Transplant 2011; 26:1033-41.
8. Braun N, Reimold F, Biegger D, Fritz P, Kimmel M, Ulmer C, et al. Fibrogenic growth factors in encapsulating peritoneal sclerosis. Nephron Clin Pract 2009; 113:c88-95.
9. Kawaguchi Y, Kawanishi H, Mujais S, Topley N, Oreopoulos DG. Encapsulating peritoneal sclerosis: definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 2000; 20(Suppl 4):S43-55.
10. Augustine T, Brown PW, Davies SD, Summers AM, Wilkie ME. Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron Clin Pract 2009; 111:c149-54.
11. Nakamoto H. Encapsulating peritoneal sclerosis-a clinician's approach to diagnosis and medical treatment. Perit Dial Int 2005; 25(Suppl 4):S30-8.
12. Kawanishi H, Moriishi M, Ide K, Dohi K. Recommendation of the surgical option for treatment of encapsulating peritoneal sclerosis. Perit Dial Int 2008; 28(Suppl 3):S205-10.
13. Wong CF, Beshir S, Khalil A, Pai P, Ahmad R. Successful treatment of encapsulating peritoneal sclerosis with azathioprine and prednisolone. Perit Dial Int 2005; 25:285-7.
14. Fieren MW, Betjes MG, Korte MR, Boer WH. Posttransplant encapsulating peritoneal sclerosis: a worrying new trend? Perit Dial Int 2007; 27:619-24.
15. Bozkurt D, Sipahi S, Cetin P, Hur E, Ozdemir O, Ertilav M, et al. Does immunosuppressive treatment ameliorate morphology changes in encapsulating peritoneal sclerosis? Perit Dial Int 2009; 29(Suppl 2):S206-10.
16. Sawada T, Ishii Y, Nakajima I, Fuchinoue S, Kubota K, Teraoka S. An experimental model of encapsulating peritoneal sclerosis. Perit Dial Int 2009; 29(Suppl 2):S49-50.
17. Sawada T, Ishii Y, Tojimbara T, Nakajima I, Fuchinoue S, Teraoka S. The ACE inhibitor, quinapril, ameliorates peritoneal fibrosis in an encapsulating peritoneal sclerosis model in mice. Pharmacol Res 2002; 46:505-10.
18. Nakamoto H, Imai H, Fukushima R, Ishida Y, Yamanouchi Y, Suzuki H. Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis. Perit Dial Int 2008; 28(Suppl 3):S83-7.
19. Jing S, Kezhou Y, Hong Z, Qun W, Rong W. Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients. Nephrology (Carlton) 2010; 15:27-32.
20. Nessim SJ, Perl J, Bargman JM. The renin-angiotensin-aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum? Kidney Int 2010; 78:23-8.
21. del Peso G, Bajo MA, Gil F, Aguilera A, Ros S, Costero O, et al. Clinical experience with tamoxifen in peritoneal fibrosing syndromes. Adv Perit Dial 2003; 19:32-5.
22. Eltoum MA, Wright S, Atchley J, Mason JC. Four consecutive cases of peritoneal dialysis-related encapsulating peritoneal sclerosis treated successfully with tamoxifen. Perit Dial Int 2006; 26:203-6.
23. Summers AM, Clancy MJ, Syed F, Harwood N, Brenchley PE, Augustine T, et al. Single-center experience of encapsulating peritoneal sclerosis in patients on peritoneal dialysis for end-stage renal failure. Kidney Int 2005; 68:2381-8.
24. van Bommel EF, Hendriksz TR, Huiskes AW, Zeegers AG. Brief communication: tamoxifen therapy for nonmalignant retroperitoneal fibrosis. Ann Intern Med 2006; 144:101-6.
25. De Vriese AS, Tilton RG, Mortier S, Lameire NH. Myofibroblast transdifferentiation of mesothelial cells is mediated by RAGE and contributes to peritoneal fibrosis in uraemia. Nephrol Dial Transplant 2006; 21:2549-55.
26. Margetts PJ, Bonniaud P, Liu L, Hoff CM, Holmes CJ, West-Mays JA, et al. Transient overexpression of TGF-β1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 2005; 16:425-36.
27. Honda K, Nitta K, Horita S, Tsukada M, Itabashi M, Nihei H, et al. Histologic criteria for diagnosing encapsulating peritoneal sclerosis in continuous ambulatory peritoneal dialysis patients. Adv Perit Dial 2003; 19:169-75.
28. Vlijm A, Stoker J, Bipat S, Spijkerboer AM, Phoa SS, Maes R, et al. Computed tomographic findings characteristic for encapsulating peritoneal sclerosis: a case-control study. Perit Dial Int 2009; 29:517-22.
29. Schwab M, Reynders V, Loitsch S, Steinhilber D, Stein J, Schroder O. Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. Mol Immunol 2007; 44:3625-32.
30. Zhang Y, Kong J, Deb DK, Chang A, Li YC. Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system. J Am Soc Nephrol 2010; 21:966-73.
31. Li YC, Qiao G, Uskokovic M, Xiang W, Zheng W, Kong J. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89-90:387-92.
32. 3 is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229-38.
33. Maehle BO, Tretli S, Skjaerven R, Thorsen T. Premorbid body weight and its relations to primary tumour diameter in breast cancer patients; its dependence on estrogen and progesteron receptor status. Breast Cancer Res Treat 2001; 68:159-69.
34. Mechsner S, Weichbrodt M, Riedlinger WF, Bartley J, Kaufmann AM, Schneider A, et al. Estrogen and progestogen receptor positive endometriotic lesions and disseminated cells in pelvic sentinel lymph nodes of patients with deep infiltrating rectovaginal endometriosis: a pilot study. Hum Reprod 2008; 23:2202-9.
35. Detti L, Saed GM, Jiang ZL, Kruger ML, Diamond MP. The effect of estradiol on the expression of estrogen, progesterone, androgen, and prolactin receptors in human peritoneal fibroblasts. J Assist Reprod Genet 2008; 25:245-50.
36. Suga H, Teraoka S, Ota K, Komemushi S, Furutani S, Yamauchi S, et al. Preventive effect of pirfenidone against experimental sclerosing peritonitis in rats. Exp Toxicol Pathol 1995; 47:287-91.
37. Turner M, Holleman J. Successful therapy of sclerosing peritonitis. Semin Dial 1992; 5:316.
38. Thirunavukarasu T, Saxena R, Anijeet H, Pai P, Wong CF. Encapsulating peritoneal sclerosis presenting with recurrent ascites and tamoxifen: case reports and review of the literature. Ren Fail 2007; 29:775-6.
39. Moustafellos P, Hadjianastassiou V, Roy D, Velzeboer NE, Maniakyn N, Vaidya A, et al. Tamoxifen therapy in encapsulating sclerosing peritonitis in patients after kidney transplantation. Transplant Proc 2006; 38:2913-14.
40. Guest S. Tamoxifen therapy for encapsulating peritoneal sclerosis: mechanism of action and update on clinical experiences. Perit Dial Int 2009; 29:252-5.
41. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramirez-Huesca M, Dominguez-Jimenez C, Jimenez-Heffernan JA, et al. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 2003; 348:403-13.
42. Lo WK, Kawanishi H. Encapsulating peritoneal sclerosis-medical and surgical treatment. Perit Dial Int 2009; 29(Suppl 2):S211-14.
43. Braun N, Kimmel M, Biegger D, Fritz P, Alscher DM. Angiogenesis and cellularity in encapsulating peritoneal sclerosis. Nephrol Dial Transplant Plus 2010; 3:414-15.